The maximum dose is 320 mg daily. Maximum blood pressure reduction occurs within 4 weeks. For congestive heart failure, the usual dose is 40 mg twice daily. The doses may be increased to 80-160 mg twice daily.
OIG will be responsive to the needs of the TDCJ, the TBCJ, governmental agencies, and the people of Texas, by demonstrating a willingness and ability to impartially investigate administrative and criminal complaints, while protecting the rights of all concerned.
Not to be confused with eculizumab. Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.